GRMN’s returns

Shares of Garmin (GRMN) fell just below 7% on May 1, 2019, to close the day at $80.06. The stock is currently trading 36% above its 52-week low of $58.71 and 11% below its 52-week high of $89.72.

The stock has been in an upward trend over the last 12 months. Garmin shares have gained 36.5% in the last year and are up 27% since the start of 2019. It’s generated absolute returns of 41% in the last five years and 92% in the last three years.

Is Garmin Stock a Good Buy after Losing 7% Overnight?

Sign up for Bagels & Stox, our witty take on the top market and investment news, straight to your inbox! Whether you’re a serious investor or just want to be informed, Bagels & Stox will be your favorite email.

Analysts’ recommendations

Of the 15 analysts tracking Garmin, two have given it “buys,” ten have given it “holds,” and three have given it “sells.” Analysts’ 12-month average price target for Garmin is $78.6, and their median estimate is $79. Garmin stock is trading at a premium of 1% to analysts’ median estimate.

Garmin has a forward PE ratio of 20.22x. If we compare this with the company’s expected 2019 earnings growth of 1.6%, we’ll find that the stock seems overvalued at its current price.

What do the technical indicators say?

On May 1, Garmin closed the trading day at $80.06. Based on that price, the stock was trading as follows:

  • 5% above its 100-day moving average of $75.91
  • 6% below its 50-day moving average of $85.38
  • 8% below its 20-day moving average of $87.03


Garmin’s 14-day MACD (moving average convergence divergence) is -2.64. A stock’s MACD marks the difference between its short-term and long-term moving averages. Garmin’s MACD score indicates a downward trading trend.

Garmin has a 14-day RSI (relative strength index) score of 27, which shows that its stock is trading well into oversold territory. An RSI score of above 70 indicates that a stock is overbought, while an RSI score of below 30 indicates that a stock is oversold.

Latest articles

This year, Pfizer (PFE) stock has fallen 0.34% and Bristol-Myers Squibb (BMY) stock has fallen 6.48%. Both companies are focused on strengthening their position in the high-growth oncology and immunology markets. Let's take a closer look at each.

Walt Disney’s (DIS) latest movie, Toy Story 4, has reportedly broken records in the opening weekend with $118 million in sales. However, the opening weekend collection was behind analysts’ expectations of at least $150 million in the first weekend.

24 Jun

Will Home Depot’s Upward Momentum to Continue?

WRITTEN BY Rajiv Nanjapla

As of June 21, Home Depot (HD) was trading at $209.39, which implies a rise of 9.7% since the announcement of its first-quarter earnings on May 21. Also, the company was trading at a premium of 32.4% from its 52-week low of $158.09 and a discount of 2.8% from its 52-week high of $215.43.

On June 21, Aurora Cannabis (ACB) made an announcement that indicated that it will move towards higher margin vape products. In addition, the company also believes concentrates and edibles will command higher margins. In anticipation of this development, the company announced the expansion of its facility to capitalize on growth related to these segments.

Shares of Mondelēz International (MDLZ) are scaling new heights thanks to its stellar gains so far this year. Mondelēz stock is up 38.0% on a YTD (year-to-date) basis, and it closed at $55.25—just a shade lower than its 52-week high of $55.71—on June 21.

24 Jun

How Long Will Facebook's Libra Fuel Bitcoin Rally?

WRITTEN BY Mayur Sontakke, CFA, FRM

Ever since the news about Facebook’s (FB) cryptocurrency project broke, Bitcoin has rallied on the hope that Facebook’s entry in the space will help make cryptocurrencies mainstream. Facebook’s cryptocurrency will be called Libra and will be governed by an association with 28 founding members across industries.